Antiviral activity of broad-spectrum and enterovirus-specific inhibitors against clinical isolates of enterovirus D68
Publication date
2015-09-14
Authors
Sun, Liang
Meijer, Adam
Froeyen, Mathy
Zhang, Linlin
Thibaut, Hendrik Jan
Baggen, J.
George, Shyla
Vernachio, John
van Kuppeveld, Frank J M
Leyssen, Pieter
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
The susceptibility of ten EV-68 isolates (belonging to cluster A, B and C) to (entero-)virus inhibitors with different mechanisms of action was investigated. The 3C-protease inhibitors proved to be more efficient than enviroxime and pleconaril, which in turn were more effective than vapendavir and pirodavir. Favipiravir proved a weak inhibitor. Resistance to pleconaril maps to V69A in VP1 and resistance to rupintrivir to V104I in the 3C protease. A structural explanation is provided why both mutations may cause resistance.
Keywords
Coronacrisis-Taverne
Citation
Sun, L, Meijer, A, Froeyen, M, Zhang, L, Thibaut, H J, Baggen, J, George, S, Vernachio, J, van Kuppeveld, F J M, Leyssen, P, Hilgenfeld, R, Neyts, J & Delang, L 2015, 'Antiviral activity of broad-spectrum and enterovirus-specific inhibitors against clinical isolates of enterovirus D68', Antimicrobial Agents and Chemotherapy, vol. 59, no. 12, pp. 7782-7785. https://doi.org/10.1128/AAC.01375-15